Yu-Tsung Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yu-Tsung Huang has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Po-Ren Hsueh
Department of Laboratory Medicine, China Medical University Hospital, China Medical University
17 shared publications - Chun-Hsing Liao
Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan
11 shared publications Tai-Fen Lee
Department of Laboratory Medicine, National Taiwan University Hospital
8 shared publicationsYao-Wen Kuo
4 shared publications- Chin-Chung Shu
Department of Internal Medicine, National Taiwan University Hospital
3 shared publications Hsin-Ni Huang
Department of Laboratory Medicine, National Taiwan University Hospital
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Impact of different clarithromycin resistance in Mycobacterium abscessus lung disease: a multicenter cohort study
Macrolides remained cornerstone of Mycobacterium abscessus treatment, but emerging resistance patterns compromised therapeutic efficacies. Clarithromycin resistance can manifest as either mutational or inducible, while the clinical impacts of different resistance mechanisms in M. abscessus pulmonary disease (MAB-PD) had been poorly characterized. We conducted a multicenter retrospective cohort study from 2011 to 2023 across four tertiary centers in Taiwan. Adults with clarithromycin-resistant MAB-PD were included and stratified by resistance type: mutational vs inducible. Outcomes included all-cause 3-year mortality, microbiological clearance, and radiographic progression. Among 108 enrolled patients, 16 (14.7%) had mutational resistance and the remaining 92 had inducible type. Isolates comprised 103 M. abscessus , three M. massiliense , and two M. bolletii . Mutational resistance was associated with significantly higher 3-year mortality (18.8% vs 4.3%, P = 0.03) and lower acid-fast smear conversion rates in treated patients (18.2% vs 67.6%, P = 0.004). Multivariable analysis identified mutational clarithromycin resistance as an independent predictor of mortality (adjusted hazard ratio 5.21, 95% confidence interval 1.10–24.6, P = 0.04). Strains with mutational resistance demonstrated higher median minimal inhibitory concentrations to linezolid (24 vs 16 mg/L), cefoxitin (64 vs 32 mg/L), and amikacin (16 vs 8 mg/L). Mutational clarithromycin resistance in MAB-PD is associated with substantially worse clinical outcomes compared to inducible resistance, including higher mortality and poorer treatment responses. These findings suggested that more intensive treatment strategies might be needed for mutational clarithromycin resistance in MAB-PD. IMPORTANCE: Macrolide resistance critically undermines treatment outcomes in Mycobacterium abscessus lung disease, yet the prognostic impact of distinct resistance mechanisms has remained unclear. This multicenter study demonstrates that mutational clarithromycin resistance, although less common than inducible resistance, is associated with markedly higher mortality, poorer microbiological response, and broader multidrug resistance. These findings provide clinically actionable evidence that not all macrolide resistance is equivalent. Recognizing mutational resistance as a high-risk phenotype has important implications for risk stratification, prognostication, and treatment intensification, supporting a more personalized approach to managing MAB-LD in routine clinical practice.
- 21 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Open AccessImpact of different clarithromycin resistance in Mycobacterium abscessus lung disease: a multicenter cohort study
Macrolides remained cornerstone of Mycobacterium abscessus treatment, but emerging resistance patterns compromised therapeutic efficacies. Clarithromycin resistance can manifest as either mutational or inducible, while the clinical impacts of different resistance mechanisms in M. abscessus pulmonary disease (MAB-PD) had been poorly characterized. We conducted a multicenter retrospective cohort study from 2011 to 2023 across four tertiary centers in Taiwan. Adults with clarithromycin-resistant MAB-PD were included and stratified by resistance type: mutational vs inducible. Outcomes included all-cause 3-year mortality, microbiological clearance, and radiographic progression. Among 108 enrolled patients, 16 (14.7%) had mutational resistance and the remaining 92 had inducible type. Isolates comprised 103 M. abscessus , three M. massiliense , and two M. bolletii . Mutational resistance was associated with significantly higher 3-year mortality (18.8% vs 4.3%, P = 0.03) and lower acid-fast smear conversion rates in treated patients (18.2% vs 67.6%, P = 0.004). Multivariable analysis identified mutational clarithromycin resistance as an independent predictor of mortality (adjusted hazard ratio 5.21, 95% confidence interval 1.10–24.6, P = 0.04). Strains with mutational resistance demonstrated higher median minimal inhibitory concentrations to linezolid (24 vs 16 mg/L), cefoxitin (64 vs 32 mg/L), and amikacin (16 vs 8 mg/L). Mutational clarithromycin resistance in MAB-PD is associated with substantially worse clinical outcomes compared to inducible resistance, including higher mortality and poorer treatment responses. These findings suggested that more intensive treatment strategies might be needed for mutational clarithromycin resistance in MAB-PD. IMPORTANCE: Macrolide resistance critically undermines treatment outcomes in Mycobacterium abscessus lung disease, yet the prognostic impact of distinct resistance mechanisms has remained unclear. This multicenter study demonstrates that mutational clarithromycin resistance, although less common than inducible resistance, is associated with markedly higher mortality, poorer microbiological response, and broader multidrug resistance. These findings provide clinically actionable evidence that not all macrolide resistance is equivalent. Recognizing mutational resistance as a high-risk phenotype has important implications for risk stratification, prognostication, and treatment intensification, supporting a more personalized approach to managing MAB-LD in routine clinical practice.
- Open Access
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Effectiveness of mass spectrometry and genomic analysis in the surveillance of nontuberculous Mycobacterium in Taiwan
Nontuberculous mycobacteria (NTM) are diverse, and species-level identification remains challenging in routine diagnostics. We analyzed NTM isolates collected at three regional centers of the National Taiwan University Hospital (NTUH) from 2019 to 2024 to assess geographic variation and identification performance after implementation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Among 3,188 cases meeting the microbiological criteria for probable pulmonary NTM disease, the species distribution differed by region: Mycobacterium avium complex predominated in central Taiwan (Yunlin, 47.3%), whereas M. abscessus complex (Taipei, 26.5%) and M. kansasii (Hsinchu, 12.4%) were more common in northern Taiwan. In 2019, 14.5% of isolates were reported to be unidentified by MALDI-TOF MS; with workflow optimization and database updates, this percentage decreased but plateaued at 4.5–4.8%. Whole-genome sequencing (WGS) of 61 randomly selected persistently unidentified isolates revealed eight average nucleotide identity (ANI)-defined clusters; 55 isolates (90.2%) could not be assigned to known species using current reference databases. Two clusters detected only in Hsinchu were phylogenetically closest to M. kyorinense , with ANI values below the species demarcation threshold. Overall, we observed marked regional heterogeneity of NTM in Taiwan and a persistent identification gap that remained after MALDI-TOF MS optimization and follow-up WGS. IMPORTANCE: This study characterized regional differences in the NTM species distribution across Taiwan, and the results highlight the limitations of current identification approaches. MALDI-TOF MS identifies most isolates, but locally circulating lineages represent a persistent gap in global reference libraries. Even with whole-genome sequencing (WGS), 90.2% (55/61) of persistently unresolved isolates could not be assigned to known species in the current reference databases despite the formation of clear ANI- and phylogeny-defined clusters. These findings show that both proteomic and genomic reference resources for clinical NTM remain incomplete. Expanding regionally representative databases and performing WGS for isolates that remain unresolved by MALDI-TOF MS will be necessary to improve species-level resolution for surveillance and clinical interpretation.
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Open AccessEffectiveness of mass spectrometry and genomic analysis in the surveillance of nontuberculous Mycobacterium in Taiwan
Nontuberculous mycobacteria (NTM) are diverse, and species-level identification remains challenging in routine diagnostics. We analyzed NTM isolates collected at three regional centers of the National Taiwan University Hospital (NTUH) from 2019 to 2024 to assess geographic variation and identification performance after implementation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Among 3,188 cases meeting the microbiological criteria for probable pulmonary NTM disease, the species distribution differed by region: Mycobacterium avium complex predominated in central Taiwan (Yunlin, 47.3%), whereas M. abscessus complex (Taipei, 26.5%) and M. kansasii (Hsinchu, 12.4%) were more common in northern Taiwan. In 2019, 14.5% of isolates were reported to be unidentified by MALDI-TOF MS; with workflow optimization and database updates, this percentage decreased but plateaued at 4.5–4.8%. Whole-genome sequencing (WGS) of 61 randomly selected persistently unidentified isolates revealed eight average nucleotide identity (ANI)-defined clusters; 55 isolates (90.2%) could not be assigned to known species using current reference databases. Two clusters detected only in Hsinchu were phylogenetically closest to M. kyorinense , with ANI values below the species demarcation threshold. Overall, we observed marked regional heterogeneity of NTM in Taiwan and a persistent identification gap that remained after MALDI-TOF MS optimization and follow-up WGS. IMPORTANCE: This study characterized regional differences in the NTM species distribution across Taiwan, and the results highlight the limitations of current identification approaches. MALDI-TOF MS identifies most isolates, but locally circulating lineages represent a persistent gap in global reference libraries. Even with whole-genome sequencing (WGS), 90.2% (55/61) of persistently unresolved isolates could not be assigned to known species in the current reference databases despite the formation of clear ANI- and phylogeny-defined clusters. These findings show that both proteomic and genomic reference resources for clinical NTM remain incomplete. Expanding regionally representative databases and performing WGS for isolates that remain unresolved by MALDI-TOF MS will be necessary to improve species-level resolution for surveillance and clinical interpretation.
- Open Access
- 2 April 2026
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 59 (4) , 521-524
Comparison of BD MAX and GeneXpert for rapid detection of tuberculosis and rifampin–isoniazid resistance
- 2 April 2026
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 59 (4) , 521-524
Open AccessComparison of BD MAX and GeneXpert for rapid detection of tuberculosis and rifampin–isoniazid resistance
- Open Access
- 1 April 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (4) , e0154925
In vitro activity of aztreonam–avibactam and distribution of carbapenemase genes in ceftazidime–avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019–2023
Carbapenem-resistant Enterobacterales (CRE) pose significant treatment challenges. While ceftazidime–avibactam (CZA) is commonly used, resistance rates have been increasing. Aztreonam–avibactam (ATM–AVI) may represent a promising alternative. A total of 109,603 Enterobacterales isolates were collected from 307 sites across 63 countries between 2019 and 2023 as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. CRE were defined as isolates with a meropenem minimal inhibitory concentration (MIC) ≥2 mg/L. Susceptibility testing was conducted according to the Clinical and Laboratory Standards Institute (CLSI) 2025 guidelines, and β-lactamase genes were identified by multiplex PCR and sequencing. Of the total Enterobacterales isolates, 7,520 (7.6%) were identified as CRE, with Klebsiella species accounting for the majority (76.3%, 5,735/7,520). CZA susceptibility was 49.1% (3,696/7,520), with a significant increase in resistance from 42.1% (540/1,283) in 2019 to 61.0% (875/1,435) in 2023 ( P < 0.05). Although CRE prevalence was highest in Asia (12.2%, 2,850/23,295), the highest rate of CZA resistance was observed in Africa/Middle East (73.9%, 557/754). In contrast, ATM–AVI demonstrated the highest in vitro activity, with 97.4% (7,324/7,520) of CRE isolates exhibiting MICs ≤4 mg/L. This activity remained strong against carbapenemase-producing strains, including metallo-β-lactamase (MBL) producers. However, reduced susceptibility was observed in Escherichia (80.2%, 556/693) and Proteus (88.9%, 56/63) species. Notably, resistance to ATM–AVI among carbapenem-resistant Escherichia species was geographically clustered in India, where 9.9% (36/364) of isolates were resistant. In conclusion, ATM–AVI exhibits potent activity against global CRE, including MBL producers, and outperforms other β-lactam/β-lactamase inhibitor combinations. However, emerging resistance in Escherichia and Proteus species—particularly with regional clustering—highlights the importance of continued global surveillance.
- 1 April 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (4) , e0154925
Open AccessIn vitro activity of aztreonam–avibactam and distribution of carbapenemase genes in ceftazidime–avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019–2023
Carbapenem-resistant Enterobacterales (CRE) pose significant treatment challenges. While ceftazidime–avibactam (CZA) is commonly used, resistance rates have been increasing. Aztreonam–avibactam (ATM–AVI) may represent a promising alternative. A total of 109,603 Enterobacterales isolates were collected from 307 sites across 63 countries between 2019 and 2023 as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. CRE were defined as isolates with a meropenem minimal inhibitory concentration (MIC) ≥2 mg/L. Susceptibility testing was conducted according to the Clinical and Laboratory Standards Institute (CLSI) 2025 guidelines, and β-lactamase genes were identified by multiplex PCR and sequencing. Of the total Enterobacterales isolates, 7,520 (7.6%) were identified as CRE, with Klebsiella species accounting for the majority (76.3%, 5,735/7,520). CZA susceptibility was 49.1% (3,696/7,520), with a significant increase in resistance from 42.1% (540/1,283) in 2019 to 61.0% (875/1,435) in 2023 ( P < 0.05). Although CRE prevalence was highest in Asia (12.2%, 2,850/23,295), the highest rate of CZA resistance was observed in Africa/Middle East (73.9%, 557/754). In contrast, ATM–AVI demonstrated the highest in vitro activity, with 97.4% (7,324/7,520) of CRE isolates exhibiting MICs ≤4 mg/L. This activity remained strong against carbapenemase-producing strains, including metallo-β-lactamase (MBL) producers. However, reduced susceptibility was observed in Escherichia (80.2%, 556/693) and Proteus (88.9%, 56/63) species. Notably, resistance to ATM–AVI among carbapenem-resistant Escherichia species was geographically clustered in India, where 9.9% (36/364) of isolates were resistant. In conclusion, ATM–AVI exhibits potent activity against global CRE, including MBL producers, and outperforms other β-lactam/β-lactamase inhibitor combinations. However, emerging resistance in Escherichia and Proteus species—particularly with regional clustering—highlights the importance of continued global surveillance.
- 20 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107669
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023
- 20 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107669
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023
- Open Access
- 25 October 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (1) , 103018
Emergence of conjugative metallo-β-lactamase-encoding plasmids in the Klebsiella pneumoniae species complex: First identification of IMP-8-MCR-9.1 in K. quasipneumoniae and VIM-1 in K. variicola in Taiwan
- 25 October 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (1) , 103018
Open AccessEmergence of conjugative metallo-β-lactamase-encoding plasmids in the Klebsiella pneumoniae species complex: First identification of IMP-8-MCR-9.1 in K. quasipneumoniae and VIM-1 in K. variicola in Taiwan
- Open Access
- 8 September 2025
- Published by Scilight Press Pty Ltd in eMicrobe
- Vol. 1 (1) , 4
Galactomannan Antigenemia among People Living with HIV: An Observational Study in Taiwan, 2009–2019
Objectives: The clinical impact of elevated serum galactomannan (GM) in HIV treatment-naïve patients is unclear. We evaluated the prevalence and significance of GM antigenemia in people with HIV (PLHIV) in a talaromycosis-endemic area. Methods: From January 2009 to August 2019, we tested GM levels within a week of HIV diagnosis and reviewed initial medical records. Using a 1:1 case-control method, we matched GM-positive patients with controls to explore risk factors. We monitored GM levels in 81 patients to assess seroconversion. Results: Among 929 HIV/AIDS patients, 72 (7.8%) had positive GM tests with a median CD4 count of 324 cells/μL. None developed aspergillosis or talaromycosis after three months, and no deaths occurred during a one-year follow-up. Positive HAV (p = 0.011) and HCV (p = 0.012) serology were significantly associated with antigenemia. Patients with CD4 counts < 50 cells/μL had higher GM levels. Of 81 patients monitored, only one remained GM-positive after 1701 days. None of the initially negative patients seroconverted. Conclusions: GM antigenemia is common in PLHIV in Taiwan, but did not lead to disease after antiretroviral therapy. Continuous monitoring is preferable to immediate antifungal treatment.
- 8 September 2025
- Published by Scilight Press Pty Ltd in eMicrobe
- Vol. 1 (1) , 4
Open AccessGalactomannan Antigenemia among People Living with HIV: An Observational Study in Taiwan, 2009–2019
Objectives: The clinical impact of elevated serum galactomannan (GM) in HIV treatment-naïve patients is unclear. We evaluated the prevalence and significance of GM antigenemia in people with HIV (PLHIV) in a talaromycosis-endemic area. Methods: From January 2009 to August 2019, we tested GM levels within a week of HIV diagnosis and reviewed initial medical records. Using a 1:1 case-control method, we matched GM-positive patients with controls to explore risk factors. We monitored GM levels in 81 patients to assess seroconversion. Results: Among 929 HIV/AIDS patients, 72 (7.8%) had positive GM tests with a median CD4 count of 324 cells/μL. None developed aspergillosis or talaromycosis after three months, and no deaths occurred during a one-year follow-up. Positive HAV (p = 0.011) and HCV (p = 0.012) serology were significantly associated with antigenemia. Patients with CD4 counts < 50 cells/μL had higher GM levels. Of 81 patients monitored, only one remained GM-positive after 1701 days. None of the initially negative patients seroconverted. Conclusions: GM antigenemia is common in PLHIV in Taiwan, but did not lead to disease after antiretroviral therapy. Continuous monitoring is preferable to immediate antifungal treatment.
- Open Access
- 14 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106592
Evolving risk factors and predisposing conditions of Pneumocystis pneumonia in non-HIV patients: A seven-year multicenter study
- 14 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106592
Open AccessEvolving risk factors and predisposing conditions of Pneumocystis pneumonia in non-HIV patients: A seven-year multicenter study
- 15 April 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (2) , 107515
Rising threat of metallo-β-lactamase-producing Klebsiella oxytoca complex in Taiwan, 2013–2022
- 15 April 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (2) , 107515
Rising threat of metallo-β-lactamase-producing Klebsiella oxytoca complex in Taiwan, 2013–2022